Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growthHongyun Zhao, Bin Zheng|Nature Metabolism|2022Cited by 155
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Hongyun Zhao, Steve Chin et al.|Nature Medicine|2025Cited by 76
Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid TumorsMiao‐Zhen Qiu, Rui‐Hua Xu, Yang Zhang et al.|JAMA Oncology|2022Cited by 69
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activationFan Luo, Hongyun Zhao|Cellular and Molecular Immunology|2023Cited by 65
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumorsXiaoli Wei, Rui‐Hua Xu, Chao Ren et al.|Cancer Communications|2020Cited by 54